January 17, 2018 06:15 AM EST
R&D
Pharma

Kym­ri­ah gets speedy re­views in US and EU as No­var­tis looks to swift­ly ex­pand CAR-T in­di­ca­tions

Amber Tong

Equipped with da­ta to di­rect­ly com­pete with Gilead’s $GILD CAR-T, No­var­tis has se­cured promis­es of quick re­views of Kym­ri­ah for a sec­ond in­di­ca­tion in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

A service from the Financial Times